CD14 and rheumatoid arthritis: In addition, it has been shown that a higher number of total circulating monocytes, and higher numbers of CD14++CD16− and CD14++CD16+ monocytes subsets, predict a reduced clinical response to methotrexate (MTX) in RA patients (18), thus supporting their value in predicting the clinical response to treatment.